ArtiÔ¨Åcial Intelligence in the Life Sciences 1 (2021) 100015 
Contents lists available at ScienceDirect 
ArtiÔ¨Åcial Intelligence in the Life Sciences 
journal homepage: www.elsevier.com/locate/ailsci 
Methods & Protocols 
Iterative DeepSARM modeling for compound optimization 
Atsushi Yoshimori a , J√ºrgen Bajorath b , ‚àó 
a Institute for Theoretical Medicine, Inc., 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan 
b Department of Life Science Informatics and Data Science, B-IT, LIMES Program Unit Chemical Biology and Medicinal Chemistry, Rheinische 
Friedrich-Wilhelms-Universit√§t, Friedrich-Hirzebruch-Allee 5/6, d -53115 Bonn, Germany 
a r t i c l e 
i n f o 
Keywords: 
Structure-activity relationships 
Molecular design 
SAR matrix 
Deep learning 
Generative modeling 
Compound optimization 
a b s t r a c t 
The Structure-Activity Relationship (SAR) Matrix (SARM) method systematically extracts structurally related 
compound series from any source and organizes these series in a unique data structure formed by matrices 
similar to R-group tables from medicinal chemistry. In addition, the SARM method generates virtual analogues 
for structurally organized series that consist of new combinations of existing core structures and R-groups. For 
active compounds, SARMs visualize SAR patterns and aid in compound design. The SARM methodology and data 
structure was integrated with a recurrent neural network architecture to further expand the compound design 
capacity with deep generative models, leading to the DeepSARM approach. Herein, we present an extension of 
the DeepSARM framework for compound optimization termed iterative DeepSARM (iDeepSARM), which involves 
multiple iterations of deep generative modeling and Ô¨Åne-tuning to obtain increasingly likely active compounds 
for targets of interest. Hence, iDeepSARM adds computational hit-to-lead and lead optimization capability to the 
DeepSARM framework. In addition to detailing methodological features and calculation protocols, an exemplary 
compound design application is reported to illustrate the iDeepSARM approach. 
1. Introduction 
Computational methods for the systematic analysis and visualiza- 
tion of structure-activity relationships (SARs) are of high interest in 
medicinal chemistry [1‚Äì5] . Equally relevant are approaches providing 
computational decision support for compound (hit-to-lead and lead) 
optimization [6‚Äì10] . Most of the latter approaches employ statistical 
data analysis, identify key compounds generated during optimization 
eÔ¨Äorts, and/or monitor SAR progression. However, these methods typi- 
cally do not suggest new compounds for synthesis. The same applies to 
approaches for SAR visualization, which are mostly descriptive in na- 
ture. 
To our knowledge, there currently is only one method available that 
combines the systematic assessment of structural relationships between 
active compounds with SAR visualization and prospective compound 
design, i.e., the SAR Matrix (SARM) approach [11] . SARM analysis sug- 
gests new analogues by systematically comparing core structures and 
substituents in related analogue series (ASs) and identifying unexplored 
core-substituent combinations across these series. The compound design 
component of SARM has been extended through deep generative mod- 
eling, leading to DeepSARM [12] , which utilizes additional information 
from selected targets and associated compound data sets to further ex- 
pand the design space. 
‚àó Corresponding author at: University of Bonn, Germany. 
E-mail address: bajorath@bit.uni-bonn.de (J. Bajorath). 
Herein, we report the extension of DeepSARM for iterative 
compound optimization. In the following, we Ô¨Årst introduce the 
SARM/DeepSARM framework and then detail the iterative DeepSARM 
(iDeepSARM) approach. An exemplary compound design application is 
presented to illustrate methodological characteristics of iDeepSARM and 
its design capabilities. 
2. Methodological framework 
2.1. SAR matrix concept 
SARMs were originally designed to systematically extract ASs from 
large compound collections, organize structurally related ASs in matri- 
ces reminiscent of R-group tables, visualize SARs, and generate virtual 
candidate compounds to further expand ASs. The identiÔ¨Åcation and or- 
ganization of structurally related ASs is facilitated by a dual-step com- 
pound decomposition scheme [11] akin to fragmentation of bonds for 
the generation of matched molecular pairs (MMPs) [13] . In the Ô¨Årst step, 
exocyclic single bonds in compounds are systematically cleaved apply- 
ing size limitations for the resulting fragments, which yields keys (core 
structures, scaÔ¨Äolds) and values (substituents, R-groups) that are stored 
in an index table. This procedure identiÔ¨Åes all analogues sharing a par- 
ticular core with R-group replacements at a single site, hence deÔ¨Åning a 
matching molecular series (MMS) [5] for each structurally unique core. 
https://doi.org/10.1016/j.ailsci.2021.100015 
Received 20 October 2021; Received in revised form 14 November 2021; Accepted 16 November 2021 
Available online 20 November 2021 
2667-3185/¬© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
A. Yoshimori and J. Bajorath 
ArtiÔ¨Åcial Intelligence in the Life Sciences 1 (2021) 100015 
Fig. 1. SAR matrix generation using DeepSARM. (A) The design of the SARM data structure is illustrated using three small structurally related compound series 
(A, B, and C). Analogues from the diÔ¨Äerent series are consecutively numbered and their pK i values are reported in red. Distinguishing substituents are shown on 
a blue background and substructures diÔ¨Äerentiating scaÔ¨Äolds (keys) are colored red. In the SARM, each row contains an MMS and each column compounds from 
diÔ¨Äerent series with the same substituent (value). Existing analogues are represented by cells that are color-coded by activity. In addition, empty cells represent 
virtual analogues. The Ô¨Ågure was adopted from [15] . (B) The architecture of DeepSARM is illustrated, which consists of three LSTM encoder-decoder units. The 
Ô¨Ågure was adopted from [12] . (C) The construction of a SARM with DeepSARM is illustrated using Seq2Seq models for value 2 and value 1. Key 2 is a scaÔ¨Äold, 
which represents the input of the Seq2Seq model for generating value 2, the R 2 substituent of the key 2 scaÔ¨Äold. Key 1 is constructed from key 2 and value 2. Key 
1 is the input of the Seq2Seq model for value 1, the R 1 substituent of key 1 or key 2. The SARM is constructed from the resulting key 1 and value 1 fragments and 
color-coded by log-likelihood scores. Value 1 and value 2 Ô¨Ålters represent structural screens to remove chemically questionable substituents (SMARTS patterns of 
in-house collections of chemically undesired substructures). 
In the second step, all keys obtained in the Ô¨Årst round are re-submitted 
to fragmentation, which then identiÔ¨Åes all structurally analogous cores 
with a chemical change at a single site and the corresponding MMSs. 
Each subset of MMSs with unique structurally related cores is orga- 
nized in an individual SARM such that each row contains an MMS and 
each column compounds from diÔ¨Äerent series sharing the same R-group, 
as illustrated in Fig. 1 A . Depending on the ASs contained in a given 
compound collection and their structural relationships, varying num- 
bers of SARMs are obtained. Each cell in a SARM represents a unique 
compound. SAR information is visualized by coloring cells according to 
compound potency. Hence, structural relationships and associated activ- 
ity patterns can be traced within SARMs. Empty cells represent virtual 
analogues consisting of non-existing key-value (core-substituent) com- 
binations, as also illustrated in Fig. 1 A. Accordingly, virtual candidate 
compounds from SARMs further extend chemical space of related ASs 
and can be envisioned to form an envelope in chemical space around 
these series. The SARM methodology and resulting SARM data struc- 
ture bridge between SAR visualization and compound design. The ap- 
proach has been further extended through the integration of activity 
prediction methods [14] and molecular grid maps providing a consen- 
sus view of existing and virtual compounds organized across diÔ¨Äerent 
SARMs of a compound data set [15] . SARM analysis and selection of vir- 
tual candidates have led to the identiÔ¨Åcation of new active compounds 
for diÔ¨Äerent targets [16‚Äì18] . 
2.2. Deep learning extension 
DeepSARM was based on the idea to further expand analogue design 
by taking information from compounds with activity against diÔ¨Äerent 
targets into account that are related to the primary target of interest 
[12] . For example, a DeepSARM model can initially be trained with 
compounds active against the target family to which the target of inter- 
est belongs, followed by Ô¨Åne-tuning of the model for the primary target. 
This procedure increases the close-in analogue design capacity of the 
SARM approach. SARMs resulting from original two-step fragmentation 
can then be further expanded with novel key and value fragments and 
additional SARMs entirely consisting of novel fragments and compounds 
can be obtained. 
For generative design on the basis of key and value fragments en- 
coded as canonical SMILES strings [19] , an encoder-decoder frame- 
2 
A. Yoshimori and J. Bajorath 
ArtiÔ¨Åcial Intelligence in the Life Sciences 1 (2021) 100015 
Fig. 1. Continued 
work consisting of long short-term memory (LSTM) units [20] repre- 
sents a preferred recurrent neural network (RNN) architecture [21] . 
The encoder-decoder framework is used to derive sequence-to-sequence 
(Seq2Seq) models that translate one sequence of one-hot encoded 
SMILES strings into another [22] . The encoder LSTM transforms input 
sequences into two-state vectors in latent space and the decoder LSTM is 
trained to return the same sequences as transformed SMILES. For Deep- 
SARM, encoder-decoder units were built using keras [23] (with 256- 
dimensional latent LSTM encoding space). 
DeepSARM includes three encoder-decoder units for the generation 
of Seq2Seq models, as illustrated in Fig. 1 B . The Seq2Seq model for key 
2 (i.e., the key 2 generator) is trained using input key 2 / output key 2 
pairs, the model for value 2 using key 2 / value 2 pairs, and the model for 
value 1 using key 1 / value 1 pairs. Compounds with newly generated 
key fragments are added to an original SARM containing structurally 
analogous keys (meeting the step-2 fragmentation criterion) and hence 
further expand the SARM. 
The three Seq2Seq models are derived as follows: 
(I) Model (key 2) using key 2 (input) / key 2 (target) pairs; 
(II) Model (value 2) using key 2 (input) / value 2 (target) pairs; 
(III) Model (value 1) using key 1 (input) / value 1 (target) pairs. 
3 
A. Yoshimori and J. Bajorath 
ArtiÔ¨Åcial Intelligence in the Life Sciences 1 (2021) 100015 
Fig. 2. Components of iterative DeepSARM. The three components (steps) comprising the iDeepSARM approach are illustrated including pre-training, Ô¨Åne-tuning, 
and iterative Ô¨Åne-tuning, as discussed in the text. 
Pre-training is carried out using large numbers of compounds with 
activity against a target family and Ô¨Åne-tuning using a comparably small 
set of compounds active against the primary target. During Ô¨Åne-tuning, 
internal model weights are adjusted. 
The Seq2Seq models generate key 2, value 2, and value 1 fragments 
that are evaluated on the basis of a log-likelihood score: 
log ‚àí ùëô ùëñùëòùëíùëô ùëñ‚Ñéùëúùëúùëë ùë†ùëêùëúùëüùëí = ‚àí 
ùëá 
‚àë
ùë° =1 
ùëô ùëúùëîùëÉ (ùë• ùë° |ùë• ùë° ‚àí1 , ‚Ä¶ , ùë• 1 )
P represents the probability distribution of the decoder and T the 
number of SMILES tokens for a given fragment. The minus sign ensures 
that high probabilities result in small scores for fragment prioritization. 
A log-likelihood threshold can be applied to Ô¨Ålter fragments. Com- 
pounds are then obtained by combining newly generated key 1 and 
value 1 fragments. Further DeepSARM calculation details are provided 
in [12] . 
Fig. 1 C illustrates the generation of a SARM using the Seq2Seq mod- 
els for value 2 and value 1. Key 2 fragments provide the input for the 
Seq2Seq model generating value 2 fragments. Key 1 is then constructed 
from key 2 and value 2 fragments. The resulting key 1 fragments serve 
as is input for the Seq2Seq model of value 1. New compounds com- 
prising the SARM are then obtained by combining the resulting key 1 
and value 1 fragments. Each cell of the SARM represents a new com- 
pound and is color-coded by the combined log-likelihood score. Invalid 
SMILES strings are removed and value 1 and value 2 Ô¨Ålters are SMARTS 
screens to remove chemically undesired substituents (such as unstable 
fragments). 
3. Iterative DeepSARM 
3.1. Methodological concept and workÔ¨Çow 
The iDeepSARM approach was designed for the optimization of 
newly identiÔ¨Åed active compounds. It consists of three components 
(steps) including pre-training, Ô¨Åne-tuning and iterative Ô¨Åne-tuning, as 
summarized in Fig. 2 . Following SARM fragmentation of compounds, 
key 1 / value 1 and key 2 / value 2 pairs are used to train Seq2Seq 
model (value 1) and Seq2Seq model (value 2), respectively. Iterative 
Ô¨Åne-tuning focuses on key 2 fragments (scaÔ¨Äolds) from DeepSARM. 
Each scaÔ¨Äold represents an MMS. Value 1 and value 2 fragments serve 
as R-groups for two diÔ¨Äerent substitution sites. Newly generated value 
1 and 2 fragments are Ô¨Åltered for structural alerts (SMARTS of in-house 
collections of chemically undesired substructures) and accepted frag- 
ments are used to construct a SARM variant with pre-deÔ¨Åned dimen- 
sionality for each key 2. This SARM variant consists of value 1 / value 
2 combinations from which corresponding compounds (key 2 / value 1 
/ value 2 combinations) are enumerated and subjected to activity pre- 
diction using the molecular topographic map (MTM) approach [24] fur- 
ther described below. Structural elitism selection focuses on compounds 
with n top-ranked predicted activities, which are then subjected to re- 
fragmentation and selection of key 1 / value 1 and key 2 / value 2 pairs 
related to the key 2 fragment (scaÔ¨Äold). Newly generated key 1 / value 
1 and key 2 / value 2 pairs are then used as input data for the next Ô¨Åne- 
tuning cycle. For the initial iteration, Seq2Seq model weights are trans- 
ferred from DeepSARM Ô¨Åne-tuning. During iterative Ô¨Åne-tuning, model 
weights are updated following each cycle. Iterations are carried out un- 
4 
A. Yoshimori and J. Bajorath 
ArtiÔ¨Åcial Intelligence in the Life Sciences 1 (2021) 100015 
Fig. 3. Compound optimization using iDeepSARM. The optimization of key 2-containing compounds using iDeepSARM is illustrated. ( A ) The structure of BRD4 
inhibitor JQ1 and its key 2 are shown for which the optimization is performed. ( B ) A SARM with JQ1 key 2-containing compounds generated with DeepSARM is 
displayed, representing the starting point of the optimization (iteration i = 0). The SARM consists of 30 value 1 (R 1 ) and 30 value 2 (R 2 ) fragments yielding 900 
compounds. It is color-coded by predicted compound activity (pIC 50 ) or log-likelihood score for value 1 / value 2 combinations. ( C ) The SARM is updated with new 
value 1 and 2 fragments obtained during iterative Ô¨Åne-tuning. Results are shown for Ô¨Åve iterations ( i = 1, 2, 3, 6, 10) color-coded by compound activity. ( D ) The 
Ô¨Åve iteratively updated SARMs are color-coded by log-likelihood scores. ( E ) Value 2 and ( F ) value 1 structures from the SARM in (B) are shown (sorted in ascending 
order of likelihood). ( G ) Value 2 and ( H ) value 1 structures from the SARM for i = 10 are shown. 
Fig. 4. Iterative compound activity prediction. Mean predicted compound 
activities are reported for the SARM in Fig. 3 during iterative optimization. Error 
bars indicate standard deviations. 
til a pre-deÔ¨Åned activity threshold or number of iterations is reached. 
Success of iterative Ô¨Åne-tuning intrinsically depends on the reliability 
of compounds activity predictions and log-likelihood scores. Preferably, 
comparable trends in the progression of activity and log-likelihood esti- 
mates should be observed during the optimization procedure. 
3.2. Activity prediction 
For iDeepSARM, a new image-based activity prediction method is 
employed, i.e. MTM [24] . The approach is summarized in Supplemen- 
tary Figure S1A . The underlying idea is to use feature sets of a com- 
pound to generate a generative topographic mapping (GTM) model 
[25] that projects features onto a two-dimensional matrix and produces 
an image representation. The GTM model is calculated with the runGTM 
function of ugtm [26] . A convolutional neural network (CNN) [27] is 
then trained on molecular images of known active compounds and their 
activity data and used for activity prediction. The architecture of the 
MTM CNN is illustrated in Supplementary Figure S1B . Conv2D_1 and 
Conv2D_2 are convolution layers and MaxPooling2D_1 and MaxPool- 
ing2D_2 pooling layers. In the Dropout layer, randomly selected neurons 
are ignored during training. In the Flatten layer, a matrix is converted 
5 
A. Yoshimori and J. Bajorath 
ArtiÔ¨Åcial Intelligence in the Life Sciences 1 (2021) 100015 
Fig. 5. Ligand-target interactions. ( A ) Compound JQ1 is shown together with its MTM and the X-ray structure of its complex with BRD4 (PDB ID: 3MXF). MTM- 
based activity prediction for JQ1 is reported (experimental IC 50 value: 77 nM). ( B ) The corresponding representation is shown for a docking model of a computational 
candidate compound from iDeepSARM predicted to have higher activity (Comp001). In the complexes, carbon atoms of the ligands and selected binding site residues 
of BRD4 are colored green and cyan, respectively (otherwise, standard atom coloring is used). Remaining parts of BRD4 are depicted as a ribbon representation. 
into a single array. Dense_1 and _2 represent fully connected layers. The 
CNN structure was implemented using keras [23] . An attractive feature 
of the MTM approach is the ability to visualize feature set (dis)similarity 
of test compounds to complement activity prediction. However, a major 
motivation for using MTM for iDeepSARM is data augmentation, which 
is required when only small compound sets are available for Ô¨Åne-tuning. 
For images, a robust data augmentation approach is available that gen- 
erates hybrid images from pairs of images on the basis of continuously 
valued mixing coeÔ¨Écients [28] , which also enables precise calculation 
of associated hypothetical activity values. 
For the calculations reported below, atomic features sets were cal- 
culated using an algorithm [24] similar to the one for generating the 
extended connectivity Ô¨Ångerprint with bond diameter 4 (ECFP4) [29] . 
For runGTM, the following parameters were used: k = 28, m = 2; k is the 
square root of the number of GTM nodes and m the square root of the 
number of radial basis function centers. For other parameters, default 
settings were used. After constructing the GTM model, the responsibil- 
ities of atomic features were calculated using the transform function of 
ugtm and the MTM was generated based upon the summed responsibil- 
ities. 
4. Exemplary compound design and optimization 
4.1. Design strategy 
To illustrate iDeepSARM modeling, optimization of putative multi- 
target compounds is attempted. The application was inspired by a re- 
cent study [30] where DeepSARM was used to identify candidates for 
dual-target inhibitors of a PLK1 kinase and bromodomain-containing 
protein 4 (BRD4), a chromatin-associated protein functioning as an epi- 
genetic regular [31] . Both PLK1 and BRD4 are cancer targets. In this 
compound design eÔ¨Äort, DeepSARM was pre-trained using compounds 
with activity against PLK1 or BRD4 and Ô¨Åne-tuned with PLK1/BRD4 
dual-target inhibitors [30] . Here, we have modiÔ¨Åed the design protocol 
by pre-training with inhibitors of the human kinome, followed by Ô¨Åne- 
tuning with BRD4 inhibitors and iDeepSARM optimization of BRD4 in- 
hibitory activity. Hence, generated candidate compounds are expected 
to have the potential to be multi-kinase and BRD4 inhibitors and are 
optimized for BRD4. Although we currently do not have the option to 
experimentally test preferred candidates, this design eÔ¨Äort is well suited 
to illustrate the computational iDeepSARM approach. 
4.2. Compound data and calculation parameters 
From the Kinase SARfari collection of ChEMBL [32] , 45,441 unique 
human kinase inhibitors with reliable activity measurements were se- 
lected for pre-training (step 1 in Fig. 2 ). In addition, 2280 unique BRD4 
inhibitors were extracted from ChEMBL (ID: 1,163,125). For initial Ô¨Åne- 
tuning, 1311 BRD4 inhibitors with pIC 50 ‚â• 6 were selected (step 2 in 
Fig. 2 ). For deriving the MTM CNN activity prediction model, all 2280 
inhibitors were used. 
For training of iDeepSARM‚Äôs iterative Ô¨Åne-tuning Seq2Seq models 
(step 3 in Fig. 2 ), the number of epochs was set to 10 and batch size to 
64. Key 1 / value 1 and key 2 / value 2 pairs were divided into training 
and validation sets (9:1), respectively. For iterative Ô¨Åne-tuning, temper- 
ature factors for value 1 and 2 generation were set to 1.0. Fine-tuning 
was carried out over 10 iterations. For each iteration, 100 computed 
compounds with highest predicted activity were selected as input. For 
6 
A. Yoshimori and J. Bajorath 
ArtiÔ¨Åcial Intelligence in the Life Sciences 1 (2021) 100015 
Fig. 6. Generation of new key 2 structures. ( A ) The protocol for generating new key 2 structures via iDeepSARM with the aid of data augmentation is shown. ( B ) 
At the top, the original and an exemplary predicted new key 2 are shown. The replaced ring moiety is colored red. At the bottom, SARMs comprising compounds 
containing the original (left) and new key 2 (right) with constant value 1 and 2 fragments are color-coded by predicted activity according to Fig. 3 C. 
a speciÔ¨Åc key 2, a value 1 x value 2 SARM variant with matrix dimen- 
sionality of 30 √ó30 was generated. 
For deriving the MTM CNN model, the compound/MTM data set 
was divided into training, validation, and test sets (8:1:1). The model 
is illustrated in Supplementary Figure S1B. Hyperparameters of the 
model (see legend of Supplementary Fig. 1 ) were determined using the 
optuna hyperparameter optimization software framework [33] . 
Supplementary Figure S2A and S2B show the correlation between 
predicted and experimental pIC 50 values for the training and test set, 
respectively. The results indicate reasonable accuracy of the MTM CNN 
model, with only a limited number of prediction errors greater than one 
order of magnitude for the test set. 
4.3. Iterative optimization 
In Fig. 3 A , a known BRD4 inhibitor termed JQ1 is shown together 
with its key 2 fragment that contains two substitution sites, R 1 and R 2 , 
for value 1 and value 2 fragments, respectively. For JQ1, value 1 and 
2 were predicted using DeepSARM. Fig. 3 B shows the resulting (value 
1 x value 2) SARM variant color-coded by predicted compound activ- 
ity (left) or combined log-likelihood score from Seq2Seq models. As can 
be seen, the initially generated JQ1 analogues had signiÔ¨Åcantly vary- 
ing predicted activity and the distribution of log-likelihood scores was 
dominated by relatively low values. On the basis of these input data, 
iDeepSARM optimization was carried out over 10 iterations. 
Fig. 3 C and 3 D show the corresponding SARM representations for 
Ô¨Åve iterations color-coded by predicted compound activity and log- 
likelihood scores, respectively. The SARMs displayed a clearly evident 
parallel progression towards increasing compound activity as well as 
decreasing log-likelihood and hence indicated successful compound op- 
timization. 
Supplementary Figure S3A and S3B show value 2 and 1 fragments, 
respectively, from the initial SARM ( i = 0), the starting point of the op- 
timization, and Supplementary Figure S3C and S3D value 2 and value 
1 fragments, respectively, after the Ô¨Ånal ( i = 10) iDeepSARM iteration. 
The starting structures were more diverse and the optimization increas- 
ingly prioritized substituted phenyl rings for value 2 (R 2 position) and 
aliphatic substituents or, to a lesser extent, cyclohexyl derivatives for 
value 1 (R 1 ). Fig. 4 shows the concomitant evolution of predicted com- 
pound activity over the 10 iterations. Taken together, the results provide 
a representative example of a successful iDeepSARM optimization eÔ¨Äort. 
For inhibitor JQ1, an X-ray structure in complex with BRD4 was 
available in the Protein Data Bank (PDB) [34] . Fig. 5 A shows this com- 
plex together with the MTM calculated for JQ1. For comparison, Fig. 5 B 
shows a candidate compound from the iDeepSARM optimization (des- 
ignated Comp001) that was predicted to have ‚àº50-fold higher activ- 
ity than JQ1. The MTM of this candidate compound displayed global 
similarities to the one of JQ1, but also distinct diÔ¨Äerences in projected 
feature sets, for example, an additional feature center in the lower left 
quadrant of the map. A docking model of the candidate compound was 
generated with AutoDock Vina [35] . When the candidate compound 
was docked to BRD4, the same enantiomer as observed for JQ1 in the 
X-ray structure was used. In the model, a hypothetical binding mode 
similar to JQ1 was observed with conserved interactions, but also mod- 
7 
A. Yoshimori and J. Bajorath 
ArtiÔ¨Åcial Intelligence in the Life Sciences 1 (2021) 100015 
Fig. 7. Iterative scaÔ¨Äold replacements. SARMs with constant value 1 and 2 fragments and new key 2 structures (scaÔ¨Äolds) resulting from iDeepSARM optimization 
are shown color-coded by predicted activity. Key 2 structures and corresponding scaÔ¨Äold-replacement SARMs are arranged in the order of the optimization and key 
2 log-likelihood scores are reported in parentheses. Structural modiÔ¨Åcations compared to the original key 2‚Äì01 are highlighted in red. 
ulated interaction patterns for the new substituents at the R 1 and R 2 
positions. 
4.4. iDeepSARM variant for scaÔ¨Äold replacement 
We also designed an alternative iDeepSARM architecture for key 2 
(scaÔ¨Äold) replacement. This variant further extends the design capacity 
of iDeepSARM because in addition to selecting preferred R-group com- 
binations (value 1 / value 2) for given scaÔ¨Äolds, the core structure of an 
AS can also be optimized. For this purpose, the Seq2Seq model for key 2 
( Fig. 1 B ) was used for pre-training and Ô¨Åne-tuning, as shown in Fig. 6 A . 
In the example presented herein, KinaseSARfari compounds were used 
for pre-training and the JQ1 key 2 for Ô¨Åne-tuning. 
Following compound fragmentation for pre-training, key 2 frag- 
ments pairs were generated to train the Seq2Seq (key 2) model. For 
a selected key 2, the model was then Ô¨Åne-tuned using pairs of this key 
2 and other key 2 fragments obtained by data augmentation based on 
enumeration of non-canonical SMILES [36] . Using the selected key 2 as 
input, the Ô¨Åne-tuned model was then applied to predict modiÔ¨Åed key 
2 fragments, as illustrated in Fig. 6 B . For alternative keys, SARM vari- 
ants with constant value 1 and value 2 fragments were generated and 
the resulting compounds subjected to activity predictions to select pre- 
ferred candidates. The constantly used value 1 and value 2 fragments 
were the ones shown in Supplementary Figure S3D and S3C, respec- 
tively. Using the Ô¨Åne-tuned model, 300 key 2 fragments were generated 
for iDeepSARM scaÔ¨Äold replacement. Fig. 7 shows the top 10 key 2 frag- 
ments selected by log-likelihood score. 
Compared to the value 1 and 2 (R-group) optimization for the JQ1 
scaÔ¨Äold discussed above, there was no continuous improvement in com- 
pound activity, as shown in Supplementary Figure S4 , indicating that 
the JQ1 scaÔ¨Äold was diÔ¨Écult to replace. Compounds containing key 2‚Äì
09 in Fig. 7 in which a methyl group in JQ1 was replaced with an amino 
group displayed similar activity to JQ1-containing compounds. Impor- 
tantly, the key 2 fragments obtained during optimization displayed a 
variety of structural modiÔ¨Åcations across the JQ1 scaÔ¨Äold, hence pro- 
viding proof-of-principle for iDeepSARM‚Äôs ability to optimize complex 
ring structures by generating many new structural variants. 
5. Concluding discussion 
Herein, we have introduced a computational methodology for com- 
pound optimization that builds upon the SARM/DeepSARM framework 
and further extends its molecular design capacity. The core of the iDeep- 
SARM approach is an iterative optimization scheme based upon an RNN 
architecture that uses DeepSARM results as input. Iterative Ô¨Åne-tuning 
of iDeepSARM models is supported by a new CNN-based activity pre- 
diction method as well as matrix variants for visualization. Importantly, 
iDeepSARM is applicable to optimize both R-group combinations and 
individual scaÔ¨Äolds, which represents a novel feature. For scaÔ¨Äolds con- 
sisting of complex ring systems, a variety of structural modiÔ¨Åcations are 
8 
A. Yoshimori and J. Bajorath 
ArtiÔ¨Åcial Intelligence in the Life Sciences 1 (2021) 100015 
obtained. R-group and scaÔ¨Äold optimization can be carried out in a com- 
plementary manner. Instead of activity, other molecular properties can 
also be optimized including various physico-chemical properties such 
as hydrophobicity or solubility and ADMET-relevant properties such as 
membrane permeability or metabolic stability. SARM-based visualiza- 
tion of log-likelihood and property value distributions over multiple it- 
erations makes it possible to monitor progress during optimization in 
an intuitive manner, as demonstrated for the exemplary design appli- 
cation reported herein. iDeepSARM optimization is possible for com- 
pounds with single- or multi-target activity. In addition, when only lim- 
ited numbers of compounds with activity against a target of interest are 
available, they can be exclusively used for Ô¨Åne-tuning while pre-training 
can be carried out with compounds active against related or distantly 
related targets. Furthermore, iDeepSARM modeling focuses generative 
compound design on given ASs and their structural features, consistent 
with requirements of hit-to-lead and lead optimization. Given this fo- 
cus on existing ASs, synthetic accessibility of newly designed candidates 
compounds is typically high. Currently, there are only few computa- 
tional methods available that provide support for lead optimization [6‚Äì
10] . However, these methods are statistical in nature and/or facilitate 
SAR visualization, but do not include compound design. From this point 
of view, iDeepSARM is currently unique in its ability to generate new 
candidate compounds in an iterative manner and monitor progress in 
computational optimization, which should be of interest for practical 
applications in medicinal chemistry and drug design. 
Declaration of interests 
The authors declare that they have no known competing Ô¨Ånancial 
interests or personal relationships that could have appeared to inÔ¨Çuence 
the work reported in this paper. 
Supplementary materials 
Supplementary material associated with this article can be found, in 
the online version, at doi: 10.1016/j.ailsci.2021.100015 . 
References 
[1] AgraÔ¨Åotis DK , Shemanarev M , Connolly PJ , Farnum M , Lobanov VSSAR Maps . A new 
SAR visualization technique for medicinal chemists. J Med Chem 2007;50:5926‚Äì37 . 
[2] Peltason L , Bajorath JSAR Index . Quantifying the nature of structure-activity rela- 
tionships. J Med Chem 2007;50:5571‚Äì8 . 
[3] Guha R , Van Drie JH . Structure-activity landscape index: identifying and quantifying 
activity cliÔ¨Äs. J Chem Inf Model 2008;48:646‚Äì58 . 
[4] Renner S , van Otterlo WAL , Seoane MD , M√∂cklinghoÔ¨Ä S , Hofmann B , Wetzel S , 
et al. Bioactivity-guided mapping and navigation of chemical space. Nat Chem Biol 
2009;5:585‚Äì92 . 
[5] Wawer M , Bajorath J . Local structural changes, global data views: graphical sub- 
structure-activity relationship trailing. J Med Chem 2011;54:2944‚Äì51 . 
[6] Nicolaou CA , Brown N , Pattichis CS . Molecular optimization using computational 
multi-objective methods. Curr Opin Drug Discov Develop 2007;10:316‚Äì24 . 
[7] Munson M , Lieberman H , Tserlin E , Rocnik J , Ge J , Fitzgerald M , et al. Lead opti- 
mization attrition analysis (LOAA): a novel and general methodology for medicinal 
chemistry. Drug Discov Today 2015;20:978‚Äì87 . 
[8] Shanmugasundaram V , Zhang L , Kayastha S , de la Vega de Le√≥n A , Dimova D , Ba- 
jorath J . Monitoring the progression of structure‚Äìactivity relationship information 
during lead optimization. J Med Chem 2015;59:4235‚Äì44 . 
[9] Maynard AT , Roberts CD . Quantifying, Visualizing, and Monitoring Lead Optimiza- 
tion. J Med Chem 2015;59:4189‚Äì201 . 
[10] Vogt M , Yonchev D , Bajorath J . Computational method to evaluate progress in lead 
optimization. J Med Chem 2018;61:10895‚Äì900 . 
[11] Wassermann AM , Haebel P , Weskamp N , Bajorath JSAR Matrices . Automated Ex- 
traction of Information-Rich SAR Tables from Large Compound Data Sets. J Chem 
Inf Model 2012;52:1769‚Äì76 . 
[12] Yoshimori A , Bajorath J . Deep SAR Matrix: SAR Matrix Expansion for Advanced Ana- 
log Design Using Deep Learning Architectures. Future Drug Discov 2020;2:FDD36 . 
[13] Hussain J , Rea C . Computationally EÔ¨Écient Algorithm to Identify Matched Molecu- 
lar Pairs (MMPs) in Large Data Sets. J Chem Inf Model 2010;50:339‚Äì48 . 
[14] Gupta-Ostermann D , Shanmugasundaram V , Bajorath J . Neighborhood-Based Pre- 
diction of Novel Active Compounds from SAR Matrices. J Chem Inf Model 
2014;54:801‚Äì9 . 
[15] Yoshimori A , Tanoue T , Bajorath J . Integrating the Structure-Activity Relationship 
Matrix Method with Molecular Grid Maps and Activity Landscape Models for Medic- 
inal Chemistry Applications. ACS Omega 2019;4:7061‚Äì9 . 
[16] Gupta-Ostermann D , Hirose Y , Odagami T , Kouji H , Bajorath J . Prospective Com- 
pound Design Using the ‚ÄòSAR Matrix‚Äô Method and Matrix-Derived Conditional Prob- 
abilities of Activity. F1000Res 2015;4:75 . 
[17] Asawa Y , Yoshimori A , Bajorath J , Nakamura H . Prediction of an MMP-1 Inhibitor 
Activity CliÔ¨Ä Using the SAR Matrix Approach and its Experimental Validation. Sci 
Rep 2020;10:14710 . 
[18] Utomo RY , Asawa Y , Okada S , Yoshimori A , Bajorath J , Nakamura H . Development 
of Curcumin-Based Amyloid ùõΩ Aggregation Inhibitors for Alzheimer‚Äôs Disease Using 
the SAR Matrix Approach. Bioorg Med Chem 2021;46:116357 . 
[19] Weininger D . SMILES, a Chemical Language and Information System. 1. Introduction 
to Methodology and Encoding Rules. J Chem Inf Comput Sci 1988;28 31-36 . 
[20] Hochreiter S , Schmidhuber J . Long Short-Term Memory. Neur Comput 
1997;9:1735‚Äì80 . 
[21] Zheng S , Yan X , Gu Q , Yang Y , Du Y , Lu Y , et al. QBMG: quasi-Biogenic Molecule 
Generator with Deep Recurrent Neural Network. J Cheminf 2019;11:5 . 
[22] Sutskever I , Vinyals O , Le QV . Sequence to Sequence Learning with Neural Networks. 
Adv Neur Inf Proc Sys 2014;1 3104-3112 . 
[23] Ketkar N . Introduction to keras. In: Deep learning with python. Berkeley, CA: Apress; 
2017. p. 97‚Äì111 . 
[24] Yoshimori A . Prediction of Molecular Properties Using Molecular Topographic Map. 
Molecules 2021;26:4475 . 
[25] Bishop CM , Svens√©n M , Williams CKGTM . The Generative Topographic Mapping. 
Neur Comput 1998;10:215‚Äì34 . 
[26] Gaspar HA . ugtm: a Python Package for Data Modeling and Visualization Using Gen- 
erative Topographic Mapping. J Open Res Softw 2018;6:26 . 
[27] Zhong S , Hu J , Yu X , Zhang H . Molecular Image-Convolutional Neural Network 
(CNN) Assisted QSAR Models for Predicting Contaminant Reactivity toward OH Rad- 
icals: transfer Learning, Data Augmentation and Model Interpretation. Chem Eng J 
2021;408:127998 . 
[28] Zhang, H.; Cisse, M.; Dauphin, Y.N.; Lopez-Paz, D. mixup: beyond empirical risk 
minimization. Preprint arXiv:1710.09412 (2017). 
[29] Rogers D , Hahn M . Extended-Connectivity Fingerprints. J Chem Inf Model 
2010;50:742‚Äì54 . 
[30] Yoshimori A , Bajorath J . Adapting the DeepSARM Approach for Dual-Target Ligand 
Design. J Comput-Aided Mol Des 2021;35:587‚Äì600 . 
[31] Liu Z , Wang P , Chen H , Wold EA , Tian B , Brasier AR , et al. Drug Discovery Targeting 
Bromodomain-Containing Protein 4. J Med Chem 2017;60:4533‚Äì58 . 
[32] Bento AP , Gaulton A , Hersey A , Bellis LJ , Chambers J , Davies M , Kr√ºger FA , Light Y , 
Mak L , McGlinchey S , Nowotka M , Papadatos G , Santos R , Overington JP . The 
ChEMBL Bioactivity Database: an Update. Nucleic Acids Res 2014;42:D1083‚Äì90 . 
[33] Optuna. A Hyperparameter Optimization Framework. https://github.com/optuna/ 
optuna . 
[34] Berman HM , Westbrook J , Feng Z , Gilliland G , Bhat TN , Weissig H , Shindyalov IN , 
Bourne PE . The Protein Data Bank. Nucleic Acids Res 2000;28:235‚Äì42 . 
[35] Trott O , Olson AJ . AutoDock Vina: improving the Speed and Accuracy of Docking 
with a New Scoring Function, EÔ¨Écient Optimization, and Multithreading. J Comput 
Chem 2000;31:455‚Äì61 . 
[36] Bjerrum, E.J. SMILES Enumeration as Data Augmentation for Neural Network Mod- 
eling of Molecules. Preprint arXiv:1703.07076v2 (2017). 
9 
